Plain-English translation of NCT03878459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes Mellitus research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether adding pioglitazone to dapagliflozin can help people with type 1 diabetes achieve better blood sugar control and reduce the amount of insulin they need. Dapagliflozin works by helping your kidneys remove extra glucose through urine, and researchers want to know if combining it with pioglitazone—a medication that improves how your body uses insulin—might work even better. The study will compare people who receive the medication combination to those who receive a placebo (a dummy pill with no active ingredients).
Most people with type 1 diabetes need to take more and more insulin over time, which can lead to weight gain and make their blood sugar harder to control. While dapagliflozin has shown promise as an add-on treatment, researchers believe this medication might work even better when combined with another drug, potentially helping more people reach their blood sugar goals with lower insulin doses.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication combination or a placebo while continuing your normal insulin therapy. Throughout the study, you will have regular visits to check your blood sugar levels, insulin doses, and overall health. Researchers will monitor how well the medication works and track any side effects, comparing your results to see if the new treatment helps improve your blood sugar control and reduces your insulin needs.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Israel
Kuwait